351 related articles for article (PubMed ID: 2472199)
21. Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.
Vrionis FD; Wikstrand CJ; Fredman P; Månsson JE; Svennerholm L; Bigner DD
Cancer Res; 1989 Dec; 49(23):6645-51. PubMed ID: 2479468
[TBL] [Abstract][Full Text] [Related]
22. Human melanoma antigen O-acetylated ganglioside GD3 is recognized by Cancer antennarius lectin.
Ravindranaths MH; Paulson JC; Irie RF
J Biol Chem; 1988 Feb; 263(4):2079-86. PubMed ID: 3339003
[TBL] [Abstract][Full Text] [Related]
23. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ
Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446
[TBL] [Abstract][Full Text] [Related]
24. Ganglioside signatures of primary and nodal metastatic melanoma cell lines from the same patient.
Ravindranath MH; Muthugounder S; Presser N
Melanoma Res; 2008 Feb; 18(1):47-55. PubMed ID: 18227708
[TBL] [Abstract][Full Text] [Related]
25. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.
McCaffery M; Yao TJ; Williams L; Livingston PO; Houghton AN; Chapman PB
Clin Cancer Res; 1996 Apr; 2(4):679-86. PubMed ID: 9816218
[TBL] [Abstract][Full Text] [Related]
26. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of melanoma-associated gangliosides in cancer patients.
Tai T; Cahan LD; Tsuchida T; Saxton RE; Irie RF; Morton DL
Int J Cancer; 1985 May; 35(5):607-12. PubMed ID: 3997282
[TBL] [Abstract][Full Text] [Related]
28. The addition of exogenous gangliosides to cultured human cells results in the cell type-specific expression of novel surface antigens by a biosynthetic process.
Furukawa K; Thampoe IJ; Yamaguchi H; Lloyd KO
J Immunol; 1989 Feb; 142(3):848-54. PubMed ID: 2464027
[TBL] [Abstract][Full Text] [Related]
29. Specific serological response by active immunization with GD3-bearing liposomes.
Massó O; Aliño SF; Lejarreta M; Blasco F; Piulats J
J Pharmacol Exp Ther; 1996 Sep; 278(3):1114-20. PubMed ID: 8819493
[TBL] [Abstract][Full Text] [Related]
30. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
31. Anti-GD3 monoclonal antibody analysis of childhood T-cell acute lymphoblastic leukemia: detection of a target antigen for antibody-mediated cytolysis.
Reaman GH; Taylor BJ; Merritt WD
Cancer Res; 1990 Jan; 50(1):202-5. PubMed ID: 2403416
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody.
Dippold WG; Knuth A; Meyer zum Büschenfelde KH
Cancer Res; 1984 Feb; 44(2):806-10. PubMed ID: 6362854
[TBL] [Abstract][Full Text] [Related]
33. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
Helling F; Shang A; Calves M; Zhang S; Ren S; Yu RK; Oettgen HF; Livingston PO
Cancer Res; 1994 Jan; 54(1):197-203. PubMed ID: 8261439
[TBL] [Abstract][Full Text] [Related]
34. Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3.
Hersey P; Schibeci SD; Townsend P; Burns C; Cheresh DA
Cancer Res; 1986 Dec; 46(12 Pt 1):6083-90. PubMed ID: 3022915
[TBL] [Abstract][Full Text] [Related]
35. Glycosphingolipid antigens in neural tumor cell lines and anti-glycosphingolipid antibodies in sera of patients with neural tumors.
Ariga T; Suetake K; Nakane M; Kubota M; Usuki S; Kawashima I; Yu RK
Neurosignals; 2008; 16(2-3):226-34. PubMed ID: 18253060
[TBL] [Abstract][Full Text] [Related]
36. Aberrant expression of ganglioside and asialoglycosphingolipid antigens in adult T-cell leukemia cells.
Suzuki Y; Hirabayashi Y; Matsumoto N; Kato H; Hidari K; Tsuchiya K; Matsumoto M; Hoshino H; Tozawa H; Miwa M
Jpn J Cancer Res; 1987 Oct; 78(10):1112-20. PubMed ID: 2890614
[TBL] [Abstract][Full Text] [Related]
37. O-acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant.
Cheresh DA; Reisfeld RA; Varki AP
Science; 1984 Aug; 225(4664):844-6. PubMed ID: 6206564
[TBL] [Abstract][Full Text] [Related]
38. Occurrence of tumor-associated ganglioside antigens with Hanganutziu-Deicher antigenic activity on human melanomas.
Hirabayashi Y; Higashi H; Kato S; Taniguchi M; Matsumoto M
Jpn J Cancer Res; 1987 Jun; 78(6):614-20. PubMed ID: 3112076
[TBL] [Abstract][Full Text] [Related]
39. GT3 and its O-acetylated derivative are the principal A2B5-reactive gangliosides in cultured O2A lineage cells and are down-regulated along with O-acetyl GD3 during differentiation to oligodendrocytes.
Farrer RG; Quarles RH
J Neurosci Res; 1999 Aug; 57(3):371-80. PubMed ID: 10412028
[TBL] [Abstract][Full Text] [Related]
40. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells.
Lloyd KO; Gordon CM; Thampoe IJ; DiBenedetto C
Cancer Res; 1992 Sep; 52(18):4948-53. PubMed ID: 1516051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
